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one had homozygous JAK2V617F; the 12q15 anomaly was
detected in one patient with wild-type JAK2, while two had
heterozygous JAK2V617F.
Cytogenetic changes in CIMF are well documented: þ 8,
del(20q), 7/7q, del(11q) and del(13q) are known to be
recurring nonspecific cytogenetic abnormalities, and some of
them are also detectable in PV or ET patients. In the literature,
Andrieux et al.7 reported a possible role in the association
between HMGA2 and translocation involving 12q15 in CIMF. In
the current study, we found that 12q15 anomaly does not
depend on the JAK2 mutational status; thus genetic anomaly,
independent to JAK2V617F, may exist in CIMF, and molecular
study on the 12q15 region, including HMGA2,8 may disclose
another pathogenetic pathway in CIMF. The 12q15 chromo-
somal abnormality was recurrently detected in patients with
CIMF, while der(1;7)(q10;p10) was only noted in ET patients
who had myelofibrosis with JAK2V617F.6 These findings clearly
indicate that myelofibrosis among CMPD might be cytogene-
tically heterogeneous.
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Multiple myeloma (MM) is a hematological malignancy,
characterized by the accumulation of monoclonal plasma cells
in the bone marrow (BM). MM disease progression has been
recently recognized as the result of an evolving crosstalk
between different cell types within the BM. Although genetically
abnormal plasma cells define the tumor compartment itself, the
surrounding and interwoven stroma provides the supporting
framework of the tumor. This framework includes extracellular
matrix proteins, secreted growth factors and cellular interactions
with fibroblasts, macrophages, endothelial cells, osteoblasts and
osteoclasts.1 Little attention has been given to another cell type
present in the BM cavity: namely the adipocyte. These are
absent in the BM of a new-born individual; however, their
number increases with advancing age, resulting in adipocytic
deposits occupying up to 70% of the BM cavity in elderly
persons. MM is typically a disease of the elderly with
a median age of diagnosis of 65 years and the incidence
increases with age. Knowing that with advancing age, the
BM cavity is filled with adipocytes and that MM cells
closely interact with their neighboring cells, we assumed
functional interactions between BM adipocytes and MM cells.
We studied these interactions using the 5T33MM model and the
human MM5.1 cell line. In this study, we further tried to
characterize the secreted cytokines and explored the potential
role of leptin in mediating the effects of adipocytes. We finally
evaluated the expression of leptin receptor on both murine and
human MM cells and tried to correlate this with different clinical
parameters.
From the observation that MM cells, at interstitial disease
stages, can be found in close contact with adipocytes,
functional interactions between these cells are reasonable
and prompted us to start in vitro tests. The murine BM
adipocytic cell line 14F1.1 (obtained from Professor Zipori D,
Department of Molecular Cell Biology, The Weizmann Institute
of Science, Rehovot, Israel) and primary isolated human
adipocytes were used. The 14F1.1 cells initially have a
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fibroblastoid morphology, but after reaching confluence they
start to differentiate towards adipocytes.2 Addition of an
adipogenic cocktail (2 mM insulin, 0.5 mM 3-isobutyl-1-methyl-
xanthine and 1 mM dexamethasone) finally results in a homo-
genous fat cell population (95% of the cells containing large
Oil Red O-positive lipid droplets). For confirmation with
human MM cells, primary cultured BM adipocytic cells were
used. These were isolated from femoral BM samples, obtained
from patients undergoing hip surgery at the CHU Hospital
(Liege, Belgium) after giving informed consent. Cells from
femoral BM biopsies were isolated by digestion with bacterial
collagenase for 1 h 30 min at 371C. Floating adipocytes were
separated from hematopoietic and stromal cells (sedimented
cells) by centrifugation for 10 min at 700 r.p.m. and then filtered
on a 200 mm membrane and washed twice with phosphate-
buffered saline.3
To investigate the effect of secreted soluble factors on MM
cell proliferation, we added normal and concentrated condi-
tioned medium (CM) from BM fibroblasts, BM adipocytes and
peripheral adipocytes to 5T33MMvv cells and measured their
DNA synthesis in a 3H-thymidine incorporation assay.4 Under
each condition a significant increase (up to two-, threefold)
could be detected when compared to control, but there was no
difference observed between the BM fibroblasts, peripheral and
BM adipocytes (Figure 1a) as stimulants. Direct cell–cell contact
between MM and adipocytic cells increased the DNA-synthesis
of murine 5T33MM cells about threefold (Figure 1b). These
results could be confirmed using human MM5.1 cells and
cultured human BM adipocytes (results not shown). Adhesion to
the 14F1.1 adipocytic cell line finally protected the 5T33MMvv
cells against apoptosis, assessed by FACS analysis of caspase-3
activity (Figure 1c), whereas soluble factors had no effect (results
not shown). We subsequently investigated an involvement of
adipocytes in cell migration by measuring the cells migrating to
concentrated CM from adipocytic and stromal cells using a
Transwell (Coster Elscolab, Kruibeke, Belgium) system. A
significant increase of migration towards this CM could be seen
(Figure 1d), but a similar increase was observed towards
peripheral adipocytes or BM fibroblasts. Using the human
adipocytic and myeloma cells, we confirmed these effects on
MM cell migration (results not shown).
From the previous experiments, it is clear that BM adipocytes
secrete both MM growth factors and chemokines. To identify the
cytokines secreted by BM adipocytes, we analyzed the super-
natant of 14F1.1 cells by multi-analyte profile (MAP) testing
(Rules-Based Medicine, Austin, TX, USA). Three independent
samples were analyzed in duplicate. The obtained results can be
found in Table 1. The s.d. obtained from duplicate measure-
ments of the same sample were on average 7.5%. Interexperi-
mental deviations were however larger, mainly owing to
variables like cell passage, level of confluence, concentration
efficacy, et cetera. This prompted us to use the obtained results
for a qualitative inventory rather than a quantitative one.
Looking for cytokines, differentially expressed by adipocytes,
we were interested in the adipokine leptin. By showing that the
expression of leptin receptor resulted in an inferior response to
an initiated therapy with thalidomide, Kumar et al.5 provided a
first evidence of the possible importance of the leptin–leptin
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Figure 1 BM adipocytic cells support proliferation and migration of MM cells whereas they inhibit MM cell apoptosis. The supernatants of the
BMSC, 3T3L-1 and 14F1.1 stimulated the proliferation in a same degree and in a dose-dependent manner (a). Cell–cell contact between MM and
adipocytic cells significantly increased the proliferation of 5T33MM cells (b) and protected against apoptosis (c), but there was no significant
difference between BM adipocytes and BMSC. An enhanced migration of murine MM cells towards 10 times concentrated CM of BM adipocytic
cells could be seen (d). These assays were performed in triplicate and results are shown as mean7s.d. of three independent tests.
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receptor axis in MM disease. To our knowledge, this growth
factor was however not further studied in MM disease. Reverse
transcription polymerase chain reaction (RT-PCR) (Figure 2a)
was performed for qualitative measurement of leptin expression
and demonstrated a specific band of mRNA of the BM
adipocytic cells and peripheral fat tissue, whereas this signal
could not be detected in the mRNA of 5T33MMvv cells or BM
fibroblasts. A highly sensitive enzyme-linked immunosorbent
assay (ELISA) (R&D systems, Abingdon, UK) confirmed the
secretion of leptin by 14F1.1 cells and 3T3L.1 cells (530 and
603 pg/ml respectively), whereas no leptin could be found in the
supernatants of MM cells or fibroblasts. To exert its functions,
leptin has to bind to its receptors. In mice, six different leptin
receptor isoforms have been described. The long isoform
(OB-Rb) is the one that has complete signaling capabilities
and is expressed mainly in the hypothalamus but also on many
other cell types. Figure 2a illustrates that both Ob-Ra and OB-Rb
sequences were present in the mRNA of 5T33MMvv cells. Since
isolated 5T33MMvv cells may contain stromal contamination, a
RT-PCR was also performed on 5T33MMvt cells, a clonally
identical in vitro growing variant and thus 100% pure MM,
generating the same results (data not shown). Subsequently,
functional studies were performed using recombinant murine
leptin. At concentrations from 30–250 ng/ml leptin, there was
only a moderate increase (maximum factor: 1.35) in DNA
synthesis (Figure 2b), whereas at higher concentrations a
decrease in the proliferative response of 5T33MM cells to leptin
was noted. This might be explained by a potential down-
regulation of the leptin receptor at higher concentrations of
leptin. In the same concentration range, interleukin-6 (IL)-6
increased 5T33MMvv cell proliferation by a factor 1.6. Adding
leptin to IL-6 or IGF-1, only resulted in additive effects and no
synergistic effects (results not shown). To prove the contribution
of leptin in the stimulating effects of BM adipocytes on MM
cells, 5T33MM cells were incubated with a blocking antibody
against leptin receptor, leading to a decrease in the induced
DNA synthesis with 1977.5% (Figure 2c). To confirm the
expression of the leptin receptor on human MM cells, we
performed immunohistochemistical stainings on sections of 50
different BM biopsies from newly diagnosed MM patients. We
observed strong Ob-R immunoactivity in MM cells in 50% of the
biopsies. Figure 2d illustrates a positive staining in a BM section.
Expression of the leptin receptor could not be correlated to
different prognostic parameters such as Salmon & Durie staging,
b2-microglobulin, CRP, sedimentation rate, renal failure or
global survival. Kaplan–Meier analysis of the progression free
survival after the first therapy showed that the different times to
progression tended to differ between the groups (P¼ 0.090).
Patients with a weak expression of leptin receptor had a longer
time to progression (25.33 months, s.d.¼ 5.44) compared to
patients with a strong leptin receptor (16.55 months, s.d. 2.66).
An analysis of the patient’s response to a given treatment
showed a higher response (complete or partial) rate in patients
with a weak OB-R expression (66%) compared to patients with
strong OB-R expression (44%) (P¼ 0.170). There was no
significant difference in first-line treatment between the two
subgroups.
From the results obtained in the current study, we conclude
that BM adipocytes are able to contribute in the BM
microenvironment of MM disease by affecting proliferation,
apoptosis and migration. These effects were comparable to
those of BM fibroblasts, suggesting that BM adipocytes have
equivalent functions as fibroblasts. As MM cells further invade
the BM and have a diffuse growth pattern, BM adipocytes
however disappear during disease development, whereas other
stromal cells (endothelial cells, fibroblasts) remain present and
are activated. These results suggest that the role of BM
adipocytes is mainly restricted to the initial stages of the disease
before a remodeling of the BM microenvironment has occurred.
The expression of different growth factors, chemokines and
angiogenic factors, known to be involved in MM disease
development further strengthens this hypothesis of a possible
involvement of adipocytes in MM disease.
In our experiments, no significant difference could be found
between the stimulatory effects of CM from peripheral or BM
adipocytic cells. A hallmark of MM cells is their predominant
localization in the BM of the patients during the main course of
their disease. Our group earlier showed that this selective
presence of MM cells in the marrow is owing to a combination
of a selective homing to and a selective survival and growth in
the BM.6 Because of this restricted distribution of MM cells to
the BM microenvironment, the interactions of MM cells in close
contact to BM adipocytes are likely to be more important than
interactions with adipocytic cells in peripheral organs and than
the systemic circulation of lower concentrations of adipokines.
To our knowledge, no MM growth has been reported in the
peripheral fat tissue.
Adipocytes secrete specific cytokines, playing a central role in
different biological and physiological processes. Leptin, a
product of the obese gene, is such a multifunctional cytokine
predominantly produced by adipocytes. In recent years,
different studies reported the effects of leptin on cancer cell
growth, migration and invasion, suggesting that this hormone is
capable of promoting an aggressive cancer phenotype. By
RT-PCR and ELISA, we showed that adipocytes were the only
cells within the MM microenvironment that secreted leptin.
Leptin was earlier demonstrated as a cytokine that supported
leukemic development in different models. In the biology of MM
disease, a possible functional involvement of leptin was not
published hitherto. In the interactions between BM adipocytes
and MM cells, leptin does not seem to be a predominant growth
factor, as the addition of leptin resulted only in a minor increase
Table 1 Cytokines, growth factors and chemokines secreted by BM
stromal cells and BM adipocytes, analyzed by multiplex analysis
14F1.1 (s.d.) BMSC (s.d.)
IL-1b 25.1 (3.53) 27.8 (2.83)
IL-6 1.17 (0.44) 9.67 (8.82)
IL-10 21.9 (9.79) 18.9 (7.14)
IL-12p70 12.1 (2.74) 8.5 (0.57)
IL-18 16.7 (4.28) 21.8 (10.1)
Leptin 935.4 (206) 5.2 (1.85)
Oncostatin M 16.1 (1.9) 15.2 (1.45)
Stem cell factor 231.3 (1.61) 22.3 (13.4)
VCAM-1 2911 (633) 4860 (608)
TNF-a 13.72 (0.52) 11.7 (2.3)
VEGF 7346 (6415) 1650 (2007)
FGF-9 146.3 (27) 85.48 (43.2)
FGF-basic 31.1 (5.24) 19.48 (3.9)
LIF 5.44 (1.45) 6.60 (1.2)
MCP-1 1833 (1237) 1547.50 (102.5)
MCP-3 3558 (2012) 2550.00 (989.9)
MIP-1a 5.33 (0.59) 12.50 (3.9)
MIP-1b 12.68 (0.64) 27.25 (23.4)
MIP-1g 5963 (1701) 888.40 (114)
Abbreviations: BMSC, bone marrow stromal cells; FGF, fibroblast
growth factor; IL, interleukin; s.d., standard deviation; TNF-a, tumor
necrosis factor alpha; VEGF, vascular endothelial growth factor.
Concentrations are given in pg/ml and are the result of three
independent analyses.
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of MM cell proliferation and addition of a neutralizing antibody
against leptin receptor in cocultures of 5T33MM cells and BM
adipocytes, only partially inhibited the proliferation induced by
adipocytes. These results suggest that other growth factors,
secreted by adipocytes are equally or even more important.
MAP profile showed that BM adipocytes secrete growth factors
produced by other stromal cells and known to be involved in
MM disease, such as vascular endothelial growth factor, basic
fibroblast growth factor , stem cell factor, VCAM-1, IL-1b, IL-6,
IL-10 and IL-12, oncostatin-M and tumor necrosis factor alpha
(TNF)-a. To identify the pivotal cytokines in the interactions
between BM adipocytes and MM cells, further investigations are
warranted.
Two recent studies already described the involvement of
leptin and leptin receptor in MM disease. A first study indicated
that leptin serum levels were increased in MM patients at
diagnosis compared to control patients. Although leptin levels
did not increase with advancing MM stages, leptin levels
decreased following treatment.7 Recent gene expression studies
revealed that expression of leptin receptor on MM cells was
predictive for a patients’ response to a treatment with
thalidomide.5 In our patient population, we found a hetero-
geneous expression of leptin receptor, but we were not able to
find a significant correlation between leptin receptor expression
and disease state, prognostic parameters or overall survival.
However, patients with weak leptin receptor expression tended
to have a longer progression-free survival compared to patients
with strong leptin expression.
In summary, we believe that BM adipocytes should no longer
be considered as passive bystander cells, as they are able to
contribute in the BM microenvironment of MM disease by
affecting proliferation, apoptosis and migration. Leptin takes part
in these processes by affecting proliferation. These results
strengthen the hypothesis that BM adipocytes are metabolically
active cells that participate in the different biological processes
within the BM.8
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Janus kinase mutations in the development of acute megakaryoblastic leukemia
in children with and without Down’s syndrome
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published online 19 April 2007
Children with Down’s syndrome (DS) have a 20–40-fold
increased risk of acute myeloid leukemia (AML). The unique
type of AML in DS is referred to as myeloid leukemia of Down’s
syndrome (ML-DS),1 which is characterized by the frequent
occurrence of acute megakaryoblastic leukemia (AMKL or FAB
M7-like), a low diagnostic white blood cell count (WBC), young
age and excellent outcome when reduced-intensity chemother-
apy is applied.2 Approximately 10% of the infants with DS
exhibit a postnatal megakaryocytosis syndrome commonly
called transient myeloproliferative disorder (TMD) or transient
leukemia, which resolves spontaneously in the majority of the
cases. Subsequently, approximately 20% of neonates with TMD
develop ML-DS within the first 4 years of life.
Acquired mutations in the gene encoding for the major
hematopoietic transcription factor GATA1 have been identified
in leukemic blasts from virtually all patients with ML-DS and
TMD, leading to the exclusive expression of a truncated GATA1
protein (GATA1s). Recently, two studies reported that GATA1s is
insufficient to induce leukemia in the absence of other
cooperating factors on the background of trisomy 21.3,4
Furthermore, little is known about the leukemogenesis of AMKL
in children without DS (non-DS AMKL). In childhood non-DS
AMKL, the t(1;22)(p13;q13) translocation encoding the OTT-
MAL (RBM15-MKL1) fusion protein is frequently found.
In childhood AML, mutations in tyrosine kinases lead to
dysregulated signal transduction activity, and have been
implicated as frequent aberrations that confer a proliferative
advantage to leukemic cells.5 Using a proteomic approach, two
groups recently identified several activated tyrosine kinases in
the ML-DS cell line CMK and the AMKL cell line CHRF-288-11,
lacking FLT3 or KIT mutations.6,7 Subsequent DNA sequence
analysis identified the A572 V substitution in the pseudokinase
domain of JAK3, and the T875N substitution in the JH1 domain
of JAK2. DNA analysis of JAK3 in non-DS AMKL, ML-DS and
TMD patients resulted in the identification of additional
activating mutations located in the JH2 pseudokinase domain
and in the FERM receptor binding domain.6,8 Constitutive
activation of the tyrosine kinase and transformation of hemato-
poietic cells have been shown for several of the mutant
alleles.6,7 As the JAK3 mutations were mainly found in samples
from patients with ML-DS, we speculated that JAK3 mutations
cooperate with other mutations such as GATA1s in the
pathogenesis of ML-DS.
This prompted us to screen for JAK2 and JAK3 mutations in a
cohort of 44 bone marrow or peripheral blood samples from 41
patients, including 14 patients with ML-DS, five patients with
TMD, 13 patients with non-DS AMKL and nine healthy
individuals with DS. The latter samples were obtained from
sternal aspirates from children with DS without leukemia,
undergoing elective cardiac surgery in Aarhus, Denmark, and
were used to exclude germline mutations in DS children. From
two patients with AMKL, and one patient with ML-DS, paired
initial diagnosis–relapse samples were available. The ML-DS
and TMD samples were obtained from different children
(unpaired), and provided by two collaborative groups, that is,
the AML-‘Berlin–Frankfurt–Mu¨nster’ Study Group (AML-BFM-
SG, Hannover, Germany) and the Dutch Childhood Oncology
Group (DCOG, The Hague, The Netherlands). Both study
groups performed central review of the diagnosis, classification
and clinical follow-up of the patients. All cell lines (CMK, HEL
92.1.7) were obtained from the ‘German National Resource
Centre for Biological Material (DSMZ)’, and cultured under the
recommended conditions. All investigations had been approved
by the Institutional Review Board and Ethics Committee, and
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